儿童急性淋巴细胞白血病诱导化疗期间血栓形成的危险因素与临床影响:CYP-C报告
基于加拿大CYP-C注册库的回顾性队列研究纳入2589例15岁以下急性淋巴细胞白血病患儿,45例(1.7%)在诱导化疗期间发生血栓栓塞。年龄(<1岁和≥10岁)与T细胞表型为独立预测因素;血栓栓塞与诱导失败无关,但与总生存独立相关(校正HR 2.54,95%CI 1.20-5.03),与无事件生存无关(校正HR 1.86,95%CI 0.98-3.51)。
要点
- 2589例患儿中45例(1.7%)在诱导化疗期间发生血栓栓塞。
- 年龄(<1岁和≥10岁)与T细胞表型为血栓栓塞的独立预测因素。
- 血栓栓塞与总生存独立相关(校正HR 2.54),但与诱导失败无关。
核心结论
- 在此采用当代化疗方案的儿童急性淋巴细胞白血病人群中,诱导期血栓栓塞与年龄和T细胞表型相关,并与死亡率相关,但不预测诱导失败。
研究设计与样本
- 回顾性队列研究,使用基于人群的加拿大年轻人癌症(CYP-C)注册库,纳入2000-2019年诊断的15岁以下急性淋巴细胞白血病患儿,来自安大略省以外的12家加拿大儿科中心,共2589例。
主要发现
- 2589例患儿中45例(1.7%)发生诱导期血栓栓塞。
- 单因素分析中,年龄(<1岁和≥10岁 vs 1-<10岁)、T细胞表型、高危急性淋巴细胞白血病及中枢神经系统受累均与诱导期血栓栓塞相关;多因素分析中年龄和T细胞表型仍为独立预测因素。
- 诱导失败发生于53例(2.1%);诱导期血栓栓塞与诱导失败无关(OR不可估计),与治疗强化无关(校正OR 0.66,95%CI 0.26-1.69)。
- 诱导期血栓栓塞与总生存独立相关(校正HR 2.54,95%CI 1.20-5.03),但与无事件生存无关(校正HR 1.86,95%CI 0.98-3.51)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thromboembolism (TE) is associated with reduced survival in pediatric acute lymphoblastic leukemia (ALL). It has been hypothesized that TE might signal leukemic aggressiveness. The objective was to determine risk factors for TE during ALL induction (TEind ) therapy and whether TEind is associated with treatment refractoriness. This retrospective cohort study using the population-based Cancer in Young People Canada (CYP-C) registry included children <15 years of age diagnosed with ALL (2000-2019) and treated at one of 12 Canadian pediatric centers outside of Ontario. Univariate and multivariable logistic regression models were used to determine risk factors for TEind and whether TEind predicted induction failure and ALL treatment intensification. The impact of TEind on overall and event-free survival was estimated using Cox proportional hazard regression models. The study included 2589 children, of which 45 (1.7%) developed a TEind . Age (<1 year and ≥10 years vs. 1-<10 years), T-cell phenotype, high-risk ALL, and central nervous system involvement were all associated with TEind in univariate analysis. Age and T-cell phenotype remained independent predictors of TEind in multivariable analysis. Induction failure occurred in 53 patients (2.1%). TEind was not associated with induction failure (OR: not estimable) or treatment intensification (adjusted OR [95% CI]: 0.66 [0.26-1.69]). TEind was independently associated with overall survival (adjusted HR [95% CI]: 2.54 [1.20-5.03]) but not event-free survival (adjusted HR [95% CI] 1.86 [0.98-3.51]). In this population-based study of children treated with contemporary chemotherapy protocols, TEind was associated with age and T-cell phenotype and mortality but did not predict induction failure.
引用
- Pelland-Marcotte MC, Kulkarni K, Tran TH, et al. Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C. Am J Hematol. 2024. PMID: 38164978. doi:10.1002/ajh.27171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。